LLY is trading 2.3% down at $1201.96 as investors reassess GLP-1 economics following Medicare’s new Wegovy obesity-drug pilot and broader weight-loss coverage discussions.
- The move follows a strong run over the past week, with the market shifting focus toward pricing, reimbursement, and long-term sector profitability.
- Competitive dynamics between Eli Lilly and Novo Nordisk remain a primary focus as the industry navigates evolving Medicare policies for obesity and diabetes treatments.